Lersivirine(UK 453061)

CAS No. 473921-12-9

Lersivirine(UK 453061)( Lersivirine | UK-453061 )

Catalog No. M21188 CAS No. 473921-12-9

Lersivirine(UK 453061) is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) under development for HIV infection therapy.?

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 76 Get Quote
5MG 108 Get Quote
10MG 178 Get Quote
25MG 341 Get Quote
50MG 507 Get Quote
100MG 713 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Lersivirine(UK 453061)
  • Note
    Research use only, not for human use.
  • Brief Description
    Lersivirine(UK 453061) is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) under development for HIV infection therapy.?
  • Description
    Lersivirine(UK 453061) is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) under development for HIV infection therapy.?(In Vitro):Lersivirine demonstrates excellent activity against large panels of wild type and drug-resistant HIV consistent with the encouraging profile demonstrated against the isolated RT enzymes.(In Vivo):Lersivirine (oral gavage; 0, 150, 350, and 500 mg/kg; once daily; gestation days 6 to 17, followed by cesarean section on gestation day 18. ) allows induction of hepatic metabolizing enzymes at the first 2 days at 250 mg/kg, after which the dose is increased to 500 mg/kg/day in Mated Crl:CD1(ICR) mice. Lersivirine leads to skeletal variations which related to delayed development and decreased fetal ossifications.
  • In Vitro
    Lersivirine demonstrates excellent activity against large panels of wild type and drug-resistant HIV consistent with the encouraging profile demonstrated against the isolated RT enzymes.
  • In Vivo
    Lersivirine (oral gavage; 0, 150, 350, and 500 mg/kg; once daily; gestation days 6 to 17, followed by cesarean section on gestation day 18. ) allows induction of hepatic metabolizing enzymes at the first 2 days at 250 mg/kg, after which the dose is increased to 500 mg/kg/day in Mated Crl:CD1(ICR) mice. Lersivirine leads to skeletal variations which related to delayed development and decreased fetal ossifications.
  • Synonyms
    Lersivirine | UK-453061
  • Pathway
    Microbiology/Virology
  • Target
    HIV
  • Recptor
    HIV
  • Research Area
    Inflammation/Immunology
  • Indication
    HIV-1

Chemical Information

  • CAS Number
    473921-12-9
  • Formula Weight
    310.35
  • Molecular Formula
    C17H18N4O2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:50 mg/mL (161.11 mM; Need ultrasonic)
  • SMILES
    CCc1nn(CCO)c(CC)c1Oc1cc(C#N)cc(C#N)c1
  • Chemical Name
    5-((35-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl)oxy)isophthalonitrile

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1 .Davis J et al. The effect of lersivirine a next-generation NNRTI on the pharmacokinetics of midazolam and oral contraceptives in healthy subjects. Eur J Clin Pharmacol. 2012 Nov;68(11):1567-72.
molnova catalog
related products
  • NBD-14189

    NBD-14189 (NBD14189) is a novel potent HIV-1 entry antagonist with potency as low as 63?nM against some clinical isolates.

  • GSK-364735

    GSK-364735 is a human immunodeficiency virus type 1 integrase (HIV-1 IN) inhibitor with antiviral activity and is used in the study of retroviral infections.

  • GS-9695

    GS-9695 is a potent, non-catalytic site HIV integrase inhibitor with wild type EC50 of 1.2 nM.